Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 9/20 | 0.47 |
| ▸ | MC5R | P33032 | 9/20 | 0.47 |
| ▸ | MC3R | P41968 | 9/20 | 0.47 |
| ▸ | MC1R | Q01726 | 9/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 10/20 | 0.46 |
| ▸ | ITGAV | P06756 | 6/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.46 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.46 |
| ▸ | ITGB5 | P18084 | 3/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.43 |
| ▸ | CTSG | P08311 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13234838 | 0.94 | MC4R (0.47) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL12482133 | 0.93 | MC4R (0.49) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL10033240 | 0.89 | MC4R (0.55) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL13267717 | 0.87 | MC4R (0.48) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL12148757 | 0.87 | ITGB3 (0.55) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL22970320 | 0.87 | ITGB3 (0.55) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL12307752 | 0.84 | MC4R (0.53) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL11988715 | 0.84 | ITGB3 (0.47) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL12307274 | 0.83 | MC4R (0.55) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL18507118 | 0.82 | MC4R (0.52) | MC4RMC5RMC3RMC1RITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120237444-A1 | IODINE RADIOLABELLING METHOD | GE HEALTHCARE LIMITED (GB) | 2012-09-20 | — | — | US | disclosed |
| US-20120134923-A1 | RADIOIODINATION METHOD | GE HEALTHCARE LIMITED (GB) | 2012-05-31 | — | — | US | disclosed |
| US-20100196270-A1 | RADIOFLUORINATION METHODS | GE HEALTHCARE AS (NO) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120237444-A1 | IODINE RADIOLABELLING METHOD | BTD, BTN3A1, BTF3 | MC4R 483/4885MC5R 253/4885MC3R 187/4885 |
| US-20100196270-A1 | RADIOFLUORINATION METHODS | CYP2F1, CYP4F2, CYP4F3 | MC4R 2530/4885MC5R 1392/4885MC3R 2134/4885 |
| US-20120134923-A1 | RADIOIODINATION METHOD | BTD, BTF3, BTN3A1 | MC4R 234/4885MC5R 187/4885MC3R 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.